Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial

被引：2
|
作者：
Paller, Amy [1 ]
Jett, John E. [2 ]
Hebert, Adelaide [3 ,4 ,5 ]
Brown, Philip M. [2 ]
Butners, Victoria [2 ]
Fitzgerald, Nancy [2 ]
Delgado, Marta [6 ]
Gonzalez, Mercedes E. [7 ]
Piscitelli, Stephen C. [2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[2] Dermavant Sci Inc, Morrisville, NC USA
[3] UTHealth McGovern, McGovern Sch Med, Houston, TX USA
[4] UTHealth McGovern, Childrens Mem Hermann Hosp, Houston, TX USA
[5] UTHealth McGovern Med Sch, Houston, TX USA
[6] RM Med Res Inc, Miami Lakes, FL USA
[7] Pediat Skin Res LLC, Miami, FL USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
atopic dermatitis; pediatrics; tapinarof; maximal usage trial;
D O I：
10.1093/bjd/ljad162.028
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
406
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials
    Gold, Linda Stein
    Del Rosso, James
    Ehst, Benjamin D.
    Zirwas, Matthew J.
    Green, Lawrence J.
    Brown, Philip M.
    Rubenstein, David S.
    Piscitelli, Stephen C.
    Tallman, Anna M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
  • [2] Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis
    Paller, Amy S.
    Gold, Linda Stein
    Soung, Jennifer
    Tallman, Anna M.
    Rubenstein, David S.
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (03) : 632 - 638
  • [3] Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
    Silverberg, Jonathan I.
    Eichenfield, Lawrence F.
    Hebert, Adelaide A.
    Simpson, Eric L.
    Gold, Linda Stein
    Bissonnette, Robert
    Papp, Kim A.
    Browning, John
    Kwong, Pearl
    Korman, Neil J.
    Brown, Philip M.
    Rubenstein, David S.
    Piscitelli, Stephen C.
    Somerville, Matthew C.
    Tallman, Anna M.
    Kircik, Leon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 457 - 465
  • [4] Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2-11 years: 52 week results from a maximum-use trial
    Bissonnette, Robert
    Lee, Mark S.
    Forman, Seth B.
    Gold, Linda Stein
    Kallender, Howard
    Angel, Brett
    Kuo, Yutzu
    Paller, Amy S.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [5] Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trials
    Alexis, Andrew F.
    Kircik, Leon
    Chovatiya, Raj
    Rice, Zakiya P.
    Bhutani, Tina
    Brown, Philip M.
    Piscitelli, Stephen C.
    Rubenstein, David S.
    Tallman, Anna M.
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 45 - 46
  • [6] 671-Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis
    Simpson, Eric
    Silverberg, Jonathan, I
    Bissonnette, Robert
    Gold, Linda Stein
    Armstrong, April W.
    Hebert, Adelaide A.
    Serrao, Rocco T.
    Jakus, Jeannette R.
    Brown, Philip M.
    Rubenstein, David S.
    Piscitelli, Stephen C.
    Tallman, Anna M.
    Eichenfield, Lawrence F.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [8] Once-daily crisaborole as a long-term maintenance treatment in patients with mild-to-moderate atopic dermatitis: A 52-week clinical trial
    Gower, Richard
    Xu, JinHua
    Alam, Maryam S.
    Su, John C.
    Myers, Daniela E.
    Sanders, Paul
    Vlahos, Bonnie
    Zang, Chuanbo
    Lan, Jar
    Werth, John
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [9] 0•03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis:: results of a randomized double-blind controlled trial
    Reitamo, S
    Harper, J
    Bos, JD
    Cambazard, F
    Bruijnzeel-Koomen, C
    Valk, P
    Smith, C
    Moss, C
    Dobozy, A
    Palatsi, R
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (03) : 554 - 562
  • [10] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
1